Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Improvement at day 10 43% Improvement at day 5 16% primary Viral clearance 80% Ivermectin  Okumuş et al.  LATE TREATMENT  DB RCT Is late treatment with ivermectin beneficial for COVID-19? Double-blind RCT 60 patients in Turkey (May - September 2020) Improved viral clearance with ivermectin (p=0.021) Okumuş et al., BMC Infectious Diseases, Jan 2021 Favors ivermectin Favors control

Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 Patients

Okumuş et al., BMC Infectious Diseases, doi:10.1186/s12879-021-06104-9 (date from preprint), NCT04646109
Jan 2021  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Small RCT for severe COVID-19 comparing the addition of ivermectin to SOC (low dose HCQ+AZ+favipiravir), with 30 treatment and 30 control patients in Turkey, showing lower mortality and faster clinical recovery. Authors also investigate the presence of gene mutations that alter ivermectin metabolism, predicting that ivermectin can be used safely without serious side effects in patients without MDR-1/ABCB1 and/or CYP3A4 gene mutation, and recommending monitoring and appropriate treatment if necessary when sequencing is unavailable. NCT04646109 (history).
This is the 13th of 47 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.0000002.
This is the 32nd of 100 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of death, 33.3% lower, RR 0.67, p = 0.55, treatment 6 of 30 (20.0%), control 9 of 30 (30.0%), NNT 10.
risk of no improvement at day 10, 42.9% lower, RR 0.57, p = 0.18, treatment 8 of 30 (26.7%), control 14 of 30 (46.7%), NNT 5.0.
risk of no improvement at day 5, 15.8% lower, RR 0.84, p = 0.60, treatment 16 of 30 (53.3%), control 19 of 30 (63.3%), NNT 10, primary outcome.
risk of no viral clearance, 80.0% lower, RR 0.20, p = 0.02, treatment 2 of 16 (12.5%), control 5 of 8 (62.5%), NNT 2.0, day 10.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Okumuş et al., 12 Jan 2021, Double Blind Randomized Controlled Trial, Turkey, peer-reviewed, 15 authors, study period May 2020 - September 2020, dosage 200μg/kg days 1-5, 36-50kg - 9mg, 51-65kg - 12mg, 66-79kg - 15mg, >80kg 200μg/kg, trial NCT04646109 (history).
This PaperIvermectinAll
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
Nurullah Okumuş, Neşe Demirtürk, Rıza Aytaç Çetinkaya, Rahmet Güner, İsmail Yaşar Avcı, Semiha Orhan, Petek Konya, Bengü Şaylan, Ayşegül Karalezli, Levent Yamanel, Bircan Kayaaslan, Gülden Yılmaz, Ümit Savaşçı, Fatma Eser, Gürhan Taşkın
BMC Infectious Diseases, doi:10.1186/s12879-021-06104-9
Background and objectives: An effective treatment option is not yet available for SARS-CoV2, which causes the COVID-19 pandemic and whose effects are felt more and more every day. Ivermectin is among the drugs whose effectiveness in treatment has been investigated. In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation. Materials and methods: Patients with severe COVID19 pneumonia were included in the study, which was planned as a prospective, randomized, controlled, single-blind phase 3 study. Two groups, the study group and the control group, took part in the study. Ivermectin 200 mcg/kg/day for 5 days in the form of a solution prepared for enteral use added to the reference treatment protocol -hydroxychloroquine + favipiravir + azithromycin-of patients included in the study group. Patients in the control group were given only reference treatment with 3 other drugs without ivermectin. The presence of mutations was investigated by performing sequence analysis in the mdr1/ abcab1 gene with the Sanger method in patients included in the study group according to randomization. Patients with mutations were excluded from the study and ivermectin treatment was not continued. Patients were followed for 5 days after treatment. At the end of the treatment and follow-up period, clinical response and changes in laboratory parameters were evaluated.
Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s12879-021-06104-9. Additional file 1: Supplementary Table 1 . Laboratory parameter changes. Declarations Ethics approval and consent to participate Ethics board approval (Afyonkarahisar Health Science University, Local Ethical Commitee 03.04.2020/139). All participants provided informed consent prior to study enrollment. Consent for publication Not applicable. Competing interests The authors declare that they have neither financial nor non-financial competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19. Final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the Seattle Region-Case Series, NEJM
Caly, Druce, Catton, Jans, Wagstaff, The-FDA approved drug ivermektin inhibits the replication of SARSCoV-2 in vitro, Antivir Res, doi:10.1016/j.antiviral.2020.104787
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavirritonavir in adults in hospitalized with severe Covid-19, NEJM, doi:10.1056/NEJMoa2001282
Capra, Rossi, Mattioli, Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia, Eur J Intern Med, doi:10.1016/j.ejim.2020.05.009
Chandler, Serious neurological adverse events after Ivermectin-do they occur beyond the indication of Onchocerciasis?, Am J Trop Med Hyg, doi:10.4269/ajtmh.17-0042
Choudhary, Sharma, Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance, New Microbes New Infect, doi:10.1016/j.nmni.2020.100684
Croci, Bottaro, Chan, Watanabe, Pezzullo et al., Liposomal systems as Nanocarriers for the antiviral agent Ivermectin, Int J Biomater, doi:10.1155/2016/8043983
Fei, Tong, Tao, Wang, Zhonghua et al., Value of neutrophil-to-lymphocyte ratio in the classification diagnosis of coronavirus disease, Bing Ji Jiu Xue
Gall, Klafke, Torres, Detoxification mechanisms involved in ivermectin resistance in the cattle tick , Rhipicephalus (Boophilus) microplus, Sci Rep, doi:10.1038/s41598-018-30907-7
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Henry, De Oliveira, Benoit, Plebani, Lippi, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a metaanalysis, Clin Chem Lab Med, doi:10.1515/cclm-2020-0369
Ivashchenko, Dimitriev, Vostokova, AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
Jean, Lee, Husueh, Treatment options for COVID-19: the reality and challenges, J Microbiol Immunol Infect, doi:10.1016/j.jmii.2020.03.034
Liu, Liu, Wang, Du, Ma et al., Clinical course and characteristics of patients with coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study, Aging, doi:10.18632/aging.103745
Liu, Liu, Xiang, Pu, Xiong et al., Neutrophil to lymphocyte ratio predicts critical illnes patients with 2019 coronavirus disease in the early stage, J Transl Med, doi:10.1186/s12967-020-02374-0
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase aactivity: new prospects for an old drug, J Antimicrob Chemother, doi:10.1093/jac/dks147
Meo, Alhowikan, Al-Khlaiwi, Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202002_20379
Meo, Klonoff, Akram, Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202004_21038
Mishra, Sahu, Lal, Reporting of all cardiac medications and their outcome in COVID-19, J Med Virol, doi:10.1002/jmv.25843
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (ivermectin in COvid nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19, medRxiv, doi:10.1101/2020.06.06.20124461
Sun, Qie, Liu, Ren, Li et al., Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis, J MedVirol
Wenjing, Chen, Li, Dynamic changes of D-dimer and neutrophillymphocyte countr atio as prognostic biomarkers in COVID-19, Respir Res
Winck, Ambrosino, COVID-19 pandemic and noninvasive respiratory management: every goliath needs a David: an evidence based evaluation of problems, Pulmonology, doi:10.1016/j.pulmoe.2020.04.013
Xu, Yang, Yang, Zou, Wang et al., Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China, Crit Care, doi:10.1186/s13054-020-03098-9
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/S2213-2600(20)30079-5
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.017
Zhang, Li, Zhou, The analysis of clinical characteristics of 34 novel coronovirus pneumonia cases in Ningxia Huiautonomous region, ZhonghuaLie He He Hu XizaZhi
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop